JPS6153335B2 - - Google Patents
Info
- Publication number
- JPS6153335B2 JPS6153335B2 JP56146339A JP14633981A JPS6153335B2 JP S6153335 B2 JPS6153335 B2 JP S6153335B2 JP 56146339 A JP56146339 A JP 56146339A JP 14633981 A JP14633981 A JP 14633981A JP S6153335 B2 JPS6153335 B2 JP S6153335B2
- Authority
- JP
- Japan
- Prior art keywords
- bark
- hot water
- extract
- melium
- water extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】
発明の背景
技術分野
本発明は、センダン樹皮の新規な熱水抽出物お
よびその精製物に関する。本発明の抽出物は抗悪
性新生物剤、特に抗腫瘍剤として有用である。
先行技術
センダン樹皮は漢方で苦棟皮(クレンピ)と称
し、煎じて回虫、鈎虫、条虫の駆除あるいはマラ
リア熱の治療に使用されている。しかし、センダ
ン樹皮に抗悪性新生物作用を有する成分が含まれ
ていることは従来知られていない。
発明の目的
本発明者等はセンダン樹皮に含まれている成分
の薬理作用について鋭意研究を重ねた結果、セン
ダン樹皮を特定の方法で抽出処理して得られる熱
水抽出物が優れた抗悪性新生物作用を有すること
を知つた。
従つて本発明の目的は、抗悪性新生物作用を有
するセンダン樹皮熱水抽出物を提供することにあ
る。
即ち、本発明により下記各項記載のセンダン樹
皮熱水抽出物が提供される。
(1) センダン樹皮を室温の水または極性有機溶媒
で抽出前処理し、得られた抽出残渣を熱水で抽
出処理して得られるセンダン樹皮熱水抽出物。
(2) 極性有機溶媒がアルコールである第1項記載
のセンダン樹皮熱水抽出物。
(3) アルコールがメタノールである第2項記載の
センダン樹皮熱水抽出物。
(4) センダン樹皮を室温の水または極性有機溶媒
で抽出前処理し、得られた抽出残渣を熱水で抽
出処理し、得られた抽出液をアルコール沈澱法
または透析膜法により精製して得られるセンダ
ン樹皮熱水抽出精製物。
(5) アルコール沈澱法がエタノールを使用する沈
澱法である第4項記載のセンダン樹皮熱水抽出
精製物。
(6) エタノールが50〜95%の濃度となる量該抽出
液に添加される沈澱法である第5項記載のセン
ダン樹皮熱水抽出精製物。
(7) 透析法が分画分子量6000〜10000の透析膜を
使用する方法である第4項記載のセンダン樹皮
熱水抽出精製物。
(8) 透接膜がスペクトラポア6(Spectra
Por6)(スペクトラム・メデイカル・インダス
トリー社製品)である第7項記載のセンダン樹
皮熱水抽出精製物。
本発明によつて得られるセンダン樹皮熱水抽出
物は新規物質であつて、従来公知のセンダン樹皮
抽出物、即ち、センダン樹皮を直接熱水で抽出し
て得られる物質とは異なるものである。
発明の具体的説明
本発明のセンダン樹皮熱水抽出物は、先ず、セ
ンダン樹皮を室温の水または極性有機溶媒で抽出
前処理し、得られた抽出残渣を熱水で抽出処理
し、抽出液から水分を除去することによつて得ら
れる。
本発明においてセンダン樹皮とはセンダン
(Melia azedarach L.var.japonica Makino)、タ
イロンセンダン(Melia azedarach L.)または
トウセンダン(Melia azedarach var.toosendan
Makino)の樹皮を意味する。
樹皮は乾燥細断したものが望ましく、市販の苦
棟皮が好適に使用される。
本発明の抽出物は、上記樹皮に室温(0〜40
℃)の水または極性有機溶媒を加え、室温で数時
間〜2日間抽出前処理し、あるいは極性有機溶媒
と室温の水で順次抽出前処理し、得られた抽出残
渣に熱水を加えるか、あるいは上記抽出残渣に水
を加え、その混合物を加熱沸騰させて抽出処理
し、過後、液から水を除去することにより得
られる。
本発明において抽出前処理に使用される極性有
機溶媒の例としては、メタノール、エタノール、
n−プロパノール、イソプロパノール、n−ブタ
ノールのようなアルコール、ピリジン、アセトン
等があげられる。抽出残渣に水を加えて加熱する
工程は、沸騰水浴中または直火で行うことができ
る。熱水による抽出処理時間は、原料の種類、品
質等に従つて適宜決定されるが通常数時間乃至2
日間程度である。抽出処理終了後、抽出混合物を
過することにより抽出液を得る。かくして得ら
れた抽出液を濃縮乾固、凍結乾燥あるいはスプレ
ードライ処理等で乾燥することにより目的の抽出
物が得られる。本発明においては、熱水抽出液を
アルコール沈澱処理または透析膜処理して抽出精
製物を得ることもできる。
アルコール沈澱処理を行う場合には、上記抽出
液にアルコール例えばメタノール、エタノール等
を加え、生成した沈澱を採取する。アルコールは
抽出液中のアルコール濃度が50〜95%、特に80%
前後となるような量加えるのが望ましい。抽出液
中に生成した沈澱は常法により例えば過または
遠心分離により採取し、凍結乾燥、通風乾燥また
は真空乾燥等により乾燥する。透析膜処理を行う
場合には、上記抽出液を透析膜内に入れ、水に対
して透析し、透析内液を濃縮乾固、凍結乾燥等に
より乾燥して目的の抽出精製物を得る。透析膜と
しては、分画分子量6000〜10000のもの、例えば
スペクトラ・ポア1または6(Spectra Por1ま
たは6)〔スペクトラム・メデイカル・インダス
トリーズ社(Spectrum Medical Industries Co.
)製品〕または、ビスキングチユーブ(Visking
tube)〔ユニオンカーバイト社(Union Carbide
Corp.)製品〕が使用される。
上記アルコール沈澱処理または透析膜処理にお
いては、センダン樹皮の熱水抽出液を蒸発乾固、
凍結乾燥あるいはスプレードライヤー処理して抽
出物を得、これを再び水に溶解したものに上記精
製処理を施してもよい。
また、本発明においては、前記室温の水または
極性有機溶媒による抽出前処理に先立つて、さら
に非極性有機溶媒、例えばベンゼン、トルエン、
キシレン、n−ヘキサン、クロロホルム、四塩化
炭素、酢酸エチル等によつて抽出前処理すること
もできる。
本発明におけるセンダン樹皮熱水抽出物の特性
は次の通りである。
(1) 色と形状
淡褐色粉末
(2) 紫外線吸収スペクトル
第1図に示す通りである(実施例8抽出
物)。
UVλKBr nax276nm
(3) 赤外線吸収スペクトル
第2図に示す通りである(実施例8抽出
物)。
IRνmaxcm-1:3400付近、2920、1610
(4) 溶解性
水に可溶、ベンゼン、エタノール、酢酸エチ
ルに不溶。
(5) 分子量
スペクトラポア透析の結果から10000以上
(6) 急性毒性
LD50800mg/Kg
体重20±1grの雄性ICRマウス腹腔内投与
参考までに、センダン樹皮を直接熱水で抽出し
て得られる公知抽出物の紫外線吸収スペクトルお
よび赤外線吸収スペクトルをそれぞれ第3図およ
び第4図に示す。
第1図と第3図および第2図と第4図の比較か
ら、本発明の抽出物が公知抽出物と異なる物質で
あることがわかる。
本発明のセンダン樹皮抽出物は、種々の悪性新
生物に対して抑制作用を有する。例えば、後述す
る如く、ザルコーマ180腹水ガンおよび固形ガ
ン、P388マウス白血病等に対して抑制効果を有
する。従つて各種の悪性腫瘍の治療に有用であ
る。本発明の抽出物を投与するに際しては、例え
ば、皮下注射、静脈内注射、筋肉内注射による非
経口投与、または錠剤、カプセル剤、顆粒剤、散
剤、シロツプ剤等による経口投与をあげることが
できる。本抽出物の投与量は投与経路、患者の年
令、体重、症状によつて異なるが成人男子に対し
て1日約1〜5gである。
本発明の抽出物は、常法に従つて製剤化され投
与される。例えば、本抽出物の乾燥粉末をバイア
ル等の容器にいれ、別にアンプル等の容器に生理
食塩水、ブドウ糖液あるいはカルボキシメチルセ
ルロース(CMC)懸濁液を用意し、用時粉末を
懸濁溶解して注射する。その他、エマルジヨンに
して注射してもよい。例えば油中水(W/O)型
エマルジヨンの場合は流動パラフイン等の鉱物
油、ゴマ油、ピーナツツ油等の植物油にソルビタ
ン脂肪酸エステル等の界面活性剤を組み合せて用
いる。
次に実施例および製剤例をあげて本発明をさら
に具体的に説明する。
実施例 1
市販の苦棟皮30.0gにメタノール300mlを加え
24時間抽出前処理を行ない、抽出混合物を過し
た。抽出残渣にメタノール300mlを加えて上記と
同様に抽出前処理を行なつた。この抽出前処理操
作を計3回行なつた。得られた抽出残渣に水300
mlを加え、沸騰水浴中で約2時間熱水抽出を行な
つた。この熱水抽出操作を計3回行ない、得られ
た熱水抽出液を集め、ロータリーエバポレーター
を用いて濃縮乾固し、熱水抽出物2371.7mgを得
た。
実施例 2
メタノールの代りに室温の水で抽出前処理する
以外は実施例1と同様に抽出処理操作を行ない熱
水抽出物602.4mgを得た。
実施例 3
市販の苦棟皮30.0gにメタノール300mlを加
え、室温で約24時間抽出前処理を行ない、抽出混
合物を過した。抽出残渣にメタノール300mlを
加え、上記と同様に抽出前処理を行なつた。この
抽出前処理操作を計3回行なつた。得られた抽出
残渣を実施例2と同様に室温の水で抽出前処理
し、得られた抽出残渣を熱水抽出して熱水抽出物
577.8mgを得た。
実施例 4
市販の苦棟皮の代りにセンダンの乾燥樹皮を使
用する以外は、実施例3と同様に抽出前処理操作
および抽出処理操作を行ない、熱水抽出物309.1
mgを得た。
実施例 5
市販の苦棟皮30.0gにベンゼン300mlを加え、
室温で8時間抽出前処理を行なつた。抽出混合物
を過し、残渣に再びベンゼン300mlを加え、上
記と同様に抽出前処理を行なつた。この操作を計
3回行なつた。かくして得られた抽出残渣につい
て、実施例3と同様にしてメタノール次いで室温
の水で抽出前処理を行ない、得られた抽出残渣を
熱水で抽出して熱水抽出物598.4mgを得た。
実施例 6
市販の苦棟皮の代りにセンダンの乾燥樹皮を使
用する以外は実施例5と同様に抽出前処理および
抽出処理を行ない、熱水抽出物313.2mgを得た。
実施例 7
実施例1と同様に操作して得られたセンダン樹
皮熱水抽出物1.00gを水50mlに溶かし、この水溶
液に99%エタノールをゆつくりと加え、該水溶液
中のエタノール濃度が50%になつたときに添加を
やめ、しばらく撹拌した。生成した沈澱を遠心分
離により集め、50%エタノール、99%エタノール
およびエーテルで順次洗浄し、真空下で乾燥して
センダン樹皮熱水抽出精製物277.1mgを得た。
実施例 8
実施例7においてセンダン樹皮抽出物の水溶液
中のエタノール濃度を80%とする以外は実施例7
と全く同様に操作してセンダン樹皮熱水抽出精製
物425.3mgを得た。
実施例 9
実施例1と同様に操作して得られたセンダン樹
皮熱水抽出物1.00gを微粉末とし、これに80%エ
タノールを加え、十分に撹拌懸濁させた。遠心分
離によつて不溶部分を集め、80%エタノール、99
%エタノールおよびエーテルで洗浄し、真空下で
乾燥してセンダン樹皮熱水抽出精製物626.4mgを
得た。
実施例 10
実施例1と同様に操作して得られたセンダン樹
皮熱水抽出物1.00gを水200mlに溶かし、得られ
た水溶液をスペクトラポア6(分画分子量
10000)に入れた水に対して透析した。透析内液
を濃縮乾固してセンダン樹皮熱水抽出精製物
298.7mgを得た。
製剤例 1
実施例1で得られたセンダン樹皮熱水抽出物
1000mgを無菌5%注射用ブドウ糖溶液500mlに溶
解し、この溶液を5mlずつバイアルに無菌的に分
注し、凍結乾燥した。このようにして1バイアル
中10mgのセンダン樹皮抽出物を含む製剤を得た。
用時、注射用蒸留水に溶解して使用する。
製剤例 2
上記製剤例1と同様にしてバイアル製剤をつく
つた。ただし、無菌5%注射用ブドウ糖溶液500
mlの代りに生理食塩水500mlを使用した。用時、
注射用蒸留水に溶解して使用する。
発明の具体的作用効果
上記実施例で得られたセンダン樹皮熱水抽出物
について抗悪性新生物作用の効果を測定した。
試験例 1
ザルコーマ180腹水ガンに対する効果
(試料調製)
リン酸緩衝食塩水(ギブコ社製、リン酸9.5m
Mを含む;PBS)に0.5%カルボキシメチルセル
ロース(CMC)を懸濁させた溶液に所定濃度に
なるように各画分試料を溶解させた。
(ザルコーマ180ガン細胞移植)
ICRマウス腹腔中で継代培養したザルコーマ
180ガン細胞を腹水とともにとり出し、生理食塩
水で適当に希釈して細胞数が1.0×108個/mlとな
るように調製した。この細胞懸濁液の0.1mlを4
週令雄ICRマウス腹腔へ注射器を用いて移植し
た。従つて1匹あたりの移植細胞数は1.0×107個
である。
(試料投与)
ザルコーマ180ガン細胞を移植した次の日より
1日1回連続4日間、上に調製した試料を注射器
を用いて腹腔に0.1ml投与した。1試料1濃度に
つき6匹のマウスを使用した。対照は試料の溶剤
として用いた上記CMC入りPBSを同様に投与し
たものとした。投与量の表示はマウス体重1Kgあ
たりのmg数とした。
(効果の判定法)
ガン細胞移植後7日目にそれぞれのマウスの体
重を測定した。次に腹腔に貯まつた腹水を全量と
り出した後のマウスの体重を測定した。腹水採取
前後の体重の差を腹水量とする。採取した腹水を
ヘマトクリツト管に吸い込ませ、ヘマトクリツト
測定用ローターを用いて、低温で遠心分離し、血
液のヘマトクリツト値に相当するアサイトクリツ
ト値を得た(腹水中に占めるガン細胞の割合)。
腹水量にこの値を乗ずれば全腹水中の細胞の容量
が得られる。これを全細胞容量(トータル・パツ
クト・セル・ボリユウム;TPCV)とする。対照
では、全腹水量は6〜10ml、TPCVは、1.6〜2.5
mlとなつた。
試料投与マウスのTPCVと対照投与マウスの
TPCVの比(T/C)をとつて100〜66%のもの
をガンに対する効果なし(−)、65〜41%のもの
をやや有効(+)、40〜11%のものを有効(〓)、
10〜0%のものを著効(〓)とする。結果を表1
に示す。
試験例 2
ザルコーマ180固形ガンに対する効果
(ザルコーマ180ガン細胞移植)
試験例1と同様にして1.0×108個/mlの細胞懸
濁液を調製した。この懸濁液の0.1mlを4週令、
雄ICRマウス背部皮下に注射器を用いて細胞を移
植した。
(効果判定法)
ガン細胞移植後21日目に成長したガン組織を摘
出し、その重量を測定した(1群6匹の平均
値)。この重量と対照のものとの比(T/C)を
とつて効果判定を行つた。対照のガン組織重量は
1.5〜3.5gであつた。比の値が100〜71%のもの
を無効(−)、70〜51%のものをやや有効(+)、
50〜21%のものを有効(〓)、20〜0%のものを
著効(〓)とした。結果を表1に示す。
表1に示すように本発明の抽出物はザルコーマ
180移植がんのうち、特に固形がんに対して強い
抑制効果を有している。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel hot water extract of melium bark and its purified product. The extract of the present invention is useful as an anti-neoplastic agent, especially an anti-tumor agent. Prior Art Melium bark is called kurenpi in Chinese medicine, and is decocted and used to exterminate roundworms, hookworms, and tapeworms, and to treat malarial fever. However, it has not been previously known that the bark of maize contains components that have anti-neoplastic effects. Purpose of the Invention As a result of extensive research into the pharmacological effects of the components contained in the bark of Chilium, the present inventors have found that a hot water extract obtained by extracting the bark of Chilium using a specific method is an excellent anti-malignant new product. I learned that it has biological effects. Therefore, it is an object of the present invention to provide a hot water extract of melium bark having anti-neoplastic activity. That is, the present invention provides a hot water extract of melium bark as described in each of the following items. (1) A hot water extract of chili bark obtained by pre-extracting chili bark with water or a polar organic solvent at room temperature and extracting the resulting extraction residue with hot water. (2) The melium bark hot water extract according to item 1, wherein the polar organic solvent is alcohol. (3) The melium bark hot water extract according to item 2, wherein the alcohol is methanol. (4) Pre-extraction treatment of melium bark with water or polar organic solvent at room temperature, extraction treatment of the obtained extraction residue with hot water, and purification of the obtained extract by alcohol precipitation method or dialysis membrane method. Purified hot water extract of melium bark. (5) The purified meli bark hot water extract according to item 4, wherein the alcohol precipitation method is a precipitation method using ethanol. (6) The purified hot water extract of melid bark according to item 5, which is a precipitation method in which ethanol is added to the extract in an amount to give a concentration of 50 to 95%. (7) The purified meli bark hot water extract according to item 4, wherein the dialysis method uses a dialysis membrane with a molecular weight cutoff of 6,000 to 10,000. (8) The permeable membrane is Spectrapore 6 (Spectra
Por6) (a product of Spectrum Medical Industries). The hot water extract of maize bark obtained according to the present invention is a new substance and is different from the conventionally known meli bark extract, that is, a substance obtained by directly extracting the meli bark with hot water. Detailed Description of the Invention The hot water extract of chili bark of the present invention is obtained by first pre-extracting chili bark with water or a polar organic solvent at room temperature, extracting the obtained extraction residue with hot water, and extracting it from the extract. Obtained by removing water. In the present invention, the term "meli bark" refers to melium (Melia azedarach L. var.
Makino) bark. The bark is desirably dried and shredded, and commercially available bark is suitably used. The extract of the present invention is added to the above bark at room temperature (0-40
℃) of water or a polar organic solvent and perform an extraction pretreatment at room temperature for several hours to 2 days, or sequentially perform an extraction pretreatment with a polar organic solvent and water at room temperature, and add hot water to the resulting extraction residue; Alternatively, it can be obtained by adding water to the above extraction residue, heating the mixture to boiling for extraction treatment, and removing water from the liquid after filtration. Examples of polar organic solvents used for extraction pretreatment in the present invention include methanol, ethanol,
Examples include alcohols such as n-propanol, isopropanol, and n-butanol, pyridine, and acetone. The step of adding water to the extraction residue and heating it can be performed in a boiling water bath or over an open flame. The extraction treatment time using hot water is determined as appropriate depending on the type and quality of the raw materials, but it is usually several hours to two hours.
About a day. After the extraction process is completed, the extraction mixture is filtered to obtain an extract. The desired extract is obtained by drying the extract thus obtained by concentration drying, freeze drying, spray drying, or the like. In the present invention, a purified extract can also be obtained by subjecting the hot water extract to alcohol precipitation treatment or dialysis membrane treatment. When alcohol precipitation is performed, alcohol such as methanol, ethanol, etc. is added to the above-mentioned extract, and the resulting precipitate is collected. The alcohol concentration in the extract is 50-95%, especially 80%.
It is desirable to add amounts that will be around the same amount. The precipitate formed in the extract is collected by a conventional method, for example, by filtration or centrifugation, and dried by freeze drying, ventilation drying, vacuum drying, or the like. When performing dialysis membrane treatment, the above-mentioned extract is placed in a dialysis membrane, dialyzed against water, and the dialyzed solution is dried by concentration to dryness, freeze-drying, etc. to obtain the desired extracted and purified product. The dialysis membrane has a molecular weight cutoff of 6,000 to 10,000, such as Spectra Por 1 or 6 (Spectrum Medical Industries Co.).
) product] or Visking tube (Visking
tube) [Union Carbide
Corp.) products] are used. In the above alcohol precipitation treatment or dialysis membrane treatment, the hot water extract of melium bark is evaporated to dryness,
An extract may be obtained by freeze-drying or spray-drying, and the above-mentioned purification treatment may be performed by redissolving the extract in water. Furthermore, in the present invention, prior to the extraction pretreatment with water or a polar organic solvent at room temperature, a non-polar organic solvent such as benzene, toluene, etc.
Extraction pretreatment can also be performed with xylene, n-hexane, chloroform, carbon tetrachloride, ethyl acetate, or the like. The properties of the hot water extract of melium bark in the present invention are as follows. (1) Color and shape Light brown powder (2) Ultraviolet absorption spectrum As shown in Figure 1 (Extract of Example 8). UVλ KBr nax 276nm (3) Infrared absorption spectrum As shown in Figure 2 (Extract of Example 8). IRνmaxcm -1 : around 3400, 2920, 1610 (4) Solubility Soluble in water, insoluble in benzene, ethanol, and ethyl acetate. (5) Molecular weight More than 10,000 based on the results of Spectrapore dialysis (6) Acute toxicity LD 50 800mg/Kg Intraperitoneal administration to male ICR mice weighing 20±1gr For reference, a publicly known product obtained by directly extracting the bark of Melium with hot water The ultraviolet absorption spectrum and infrared absorption spectrum of the extract are shown in FIGS. 3 and 4, respectively. A comparison between FIG. 1 and FIG. 3 and between FIG. 2 and FIG. 4 shows that the extract of the present invention is a different substance from known extracts. The melium bark extract of the present invention has an inhibitory effect on various malignant neoplasms. For example, as described below, it has a suppressive effect on Sarcoma 180 ascites cancer and solid cancer, P388 murine leukemia, and the like. Therefore, it is useful for treating various malignant tumors. When administering the extract of the present invention, for example, parenteral administration via subcutaneous injection, intravenous injection, intramuscular injection, or oral administration via tablets, capsules, granules, powders, syrups, etc. can be mentioned. . The dosage of this extract varies depending on the route of administration, age, weight, and symptoms of the patient, but is approximately 1 to 5 g per day for an adult male. The extract of the present invention is formulated and administered according to conventional methods. For example, put the dry powder of this extract in a container such as a vial, prepare physiological saline, glucose solution, or carboxymethyl cellulose (CMC) suspension in a separate container such as an ampoule, and suspend and dissolve the powder before use. Inject. Alternatively, it may be injected in the form of an emulsion. For example, in the case of a water-in-oil (W/O) emulsion, a mineral oil such as liquid paraffin, a vegetable oil such as sesame oil or peanut oil, and a surfactant such as sorbitan fatty acid ester are used in combination. Next, the present invention will be explained in more detail with reference to Examples and Formulation Examples. Example 1 Add 300 ml of methanol to 30.0 g of commercially available turmeric.
Extraction pretreatment was performed for 24 hours and the extraction mixture was filtered. 300 ml of methanol was added to the extraction residue and pre-extraction treatment was performed in the same manner as above. This extraction pretreatment operation was performed three times in total. Water 300% to the obtained extraction residue
ml and hot water extraction was carried out in a boiling water bath for about 2 hours. This hot water extraction operation was performed three times in total, and the resulting hot water extracts were collected and concentrated to dryness using a rotary evaporator to obtain 2371.7 mg of hot water extract. Example 2 The extraction procedure was carried out in the same manner as in Example 1, except that water at room temperature was used instead of methanol for extraction pretreatment to obtain 602.4 mg of a hot water extract. Example 3 300 ml of methanol was added to 30.0 g of commercially available Chimundan bark, pre-extraction treatment was carried out at room temperature for about 24 hours, and the extraction mixture was filtered. 300 ml of methanol was added to the extraction residue, and extraction pretreatment was performed in the same manner as above. This extraction pretreatment operation was performed three times in total. The obtained extraction residue was pretreated with room temperature water in the same manner as in Example 2, and the obtained extraction residue was extracted with hot water to obtain a hot water extract.
577.8mg was obtained. Example 4 Extraction pretreatment and extraction treatment operations were carried out in the same manner as in Example 3, except that dried melium bark was used instead of commercially available bittern bark, and hot water extract 309.1 was obtained.
I got mg. Example 5 300 ml of benzene was added to 30.0 g of commercially available kumungha,
Extraction pretreatment was performed for 8 hours at room temperature. The extraction mixture was filtered, 300 ml of benzene was again added to the residue, and extraction pretreatment was performed in the same manner as above. This operation was performed three times in total. The thus obtained extraction residue was subjected to extraction pretreatment using methanol and then room temperature water in the same manner as in Example 3, and the obtained extraction residue was extracted with hot water to obtain 598.4 mg of a hot water extract. Example 6 Extraction pretreatment and extraction treatment were carried out in the same manner as in Example 5, except that dried melium bark was used instead of commercially available chili bark, to obtain 313.2 mg of a hot water extract. Example 7 1.00 g of hot water extract of chili bark obtained by the same procedure as in Example 1 was dissolved in 50 ml of water, and 99% ethanol was slowly added to this aqueous solution until the ethanol concentration in the aqueous solution was 50%. When the temperature reached 100, the addition was stopped and the mixture was stirred for a while. The generated precipitate was collected by centrifugation, washed successively with 50% ethanol, 99% ethanol and ether, and dried under vacuum to obtain 277.1 mg of a purified hot water extract of melium bark. Example 8 Example 7 except that in Example 7, the ethanol concentration in the aqueous solution of melium bark extract was 80%.
In exactly the same manner as above, 425.3 mg of purified meli bark hot water extract was obtained. Example 9 1.00 g of hot water extract of chili bark obtained in the same manner as in Example 1 was made into a fine powder, 80% ethanol was added thereto, and the mixture was thoroughly stirred and suspended. Collect the insoluble portion by centrifugation, 80% ethanol, 99%
% ethanol and ether, and dried under vacuum to obtain 626.4 mg of purified meli bark hot water extract. Example 10 1.00 g of the hot water extract of chili bark obtained by the same procedure as in Example 1 was dissolved in 200 ml of water, and the resulting aqueous solution was mixed with Spectrapore 6 (molecular weight cutoff).
10,000) and dialyzed against water. Concentrate and dry the dialysis fluid to obtain a purified hot water extract from chili bark.
298.7mg was obtained. Formulation Example 1 Meli bark hot water extract obtained in Example 1
1000 mg was dissolved in 500 ml of a sterile 5% glucose solution for injection, and 5 ml of this solution was aseptically dispensed into vials and freeze-dried. A formulation containing 10 mg of melium bark extract in one vial was thus obtained.
Before use, dissolve in distilled water for injection. Formulation Example 2 A vial preparation was prepared in the same manner as in Formulation Example 1 above. However, sterile 5% glucose solution for injection 500
500 ml of physiological saline was used instead of ml. When using,
Use by dissolving in distilled water for injection. Specific Effects of the Invention The anti-neoplastic effect of the hot water extract of chili bark obtained in the above example was measured. Test example 1 Effect on Sarcoma 180 ascites cancer (sample preparation) Phosphate buffered saline (manufactured by Gibco, phosphoric acid 9.5m
Each fraction sample was dissolved in a solution of 0.5% carboxymethyl cellulose (CMC) suspended in PBS) to a predetermined concentration. (Sarcoma 180 cancer cell transplantation) Sarcoma subcultured in the peritoneal cavity of ICR mice
180 cancer cells were taken out together with ascites fluid and diluted appropriately with physiological saline so that the number of cells was 1.0 x 10 8 cells/ml. 4 0.1 ml of this cell suspension
It was transplanted into the abdominal cavity of a week-old male ICR mouse using a syringe. Therefore, the number of transplanted cells per animal was 1.0×10 7 cells. (Sample Administration) Starting from the next day after transplanting the Sarcoma 180 cancer cells, 0.1 ml of the sample prepared above was administered into the abdominal cavity once a day for 4 consecutive days using a syringe. Six mice were used per sample per concentration. As a control, the above-mentioned PBS containing CMC, which was used as a solvent for the sample, was administered in the same manner. The dosage was expressed as mg per kg of mouse body weight. (Method for determining efficacy) The weight of each mouse was measured on the 7th day after cancer cell transplantation. Next, the weight of the mouse was measured after removing the entire amount of ascites that had accumulated in the abdominal cavity. The difference in body weight before and after ascites collection is considered the amount of ascites. The collected ascites fluid was sucked into a hematocrit tube and centrifuged at low temperature using a hematocrit measuring rotor to obtain an acytocrit value (percentage of cancer cells in the ascites), which corresponds to the hematocrit value of blood.
Multiplying the amount of ascites by this value gives the volume of cells in the total ascites. This is defined as the total cell volume (TPCV). In controls, the total ascitic fluid volume was 6-10 ml, and the TPCV was 1.6-2.5.
It became ml. TPCV of sample-treated mice and control-treated mice
Taking the TPCV ratio (T/C), those with 100-66% are not effective against cancer (-), those with 65-41% are somewhat effective (+), and those with 40-11% are effective (〓) ,
10% to 0% is considered to be markedly effective (〓). Table 1 shows the results.
Shown below. Test Example 2 Effect on Sarcoma 180 Solid Cancer (Sarcoma 180 Cancer Cell Transplantation) A cell suspension of 1.0×10 8 cells/ml was prepared in the same manner as in Test Example 1. 0.1ml of this suspension at 4 weeks of age
Cells were transplanted subcutaneously into the back of male ICR mice using a syringe. (Efficacy evaluation method) Cancer tissue that had grown on the 21st day after cancer cell transplantation was removed and its weight was measured (average value of 6 animals per group). The effect was determined by determining the ratio (T/C) between this weight and that of the control. The control cancer tissue weight is
It was 1.5 to 3.5 g. Ratio values of 100 to 71% are invalid (-), ratios of 70 to 51% are slightly valid (+),
50% to 21% was considered effective (〓), and 20% to 0% was considered extremely effective (〓). The results are shown in Table 1. As shown in Table 1, the extract of the present invention
Among the 180 transplanted cancers, it has a particularly strong suppressive effect on solid tumors.
【表】【table】
【表】
センダン樹皮熱水抽出物(実施例8抽出精製
物)の最小有効投与量は次の通りである。
ザルコーマ180腹水ガン 50mg/Kg
ザルコーマ180固形ガン 22mg/Kg
試験例 3
P388マウス白血病に対する効果
4〜5週令雄のCDF1マウスの腹腔にP388細胞
懸濁液0.1ml(細胞数1×106個)を接種した。24
時間後から1日1回計5日間、所定量の試料を含
む0.5%カルボキシメチルセルロースナトリウム
塩懸濁液0.1mlを腹腔内に投与した。平均生存日
数を求め、処置群(T)と対照群(C)との比率
(T/C%)を求めた。対照群の平均生存日数は
7〜12日であつた。T/C≧125%で活性がある
といえる。結果を表2に示す。[Table] The minimum effective dosage of the hot water extract of melium bark (extract purified product of Example 8) is as follows. Sarcoma 180 Ascites Cancer 50mg/Kg Sarcoma 180 Solid Cancer 22mg/Kg Test Example 3 Effect on P388 Mouse Leukemia Inject 0.1ml of P388 cell suspension into the peritoneal cavity of a 4-5 week old male CDF 1 mouse (number of cells: 1 x 106 ) ) was inoculated. twenty four
After that time, 0.1 ml of a 0.5% carboxymethyl cellulose sodium salt suspension containing a predetermined amount of the sample was intraperitoneally administered once a day for a total of 5 days. The average survival days were determined, and the ratio (T/C%) between the treated group (T) and the control group (C) was determined. The average survival time of the control group was 7-12 days. It can be said that there is activity when T/C≧125%. The results are shown in Table 2.
【表】
試験例 4
定着固形ガンに対する効果
ザルコーマ180細胞1×107個をICRマウス(5
匹)背部皮下に移植し、そのまま2週間飼育し
た。皮下に移植したザルコーマ180が1000〜1500
mm3(12×15mm程度)に成長しているのを確認し
た後、移植後14日目から、実施例8で得られたセ
ンダン樹皮熱水抽出精製物を腹腔内に1日1回
150mg/Kgを5日間投与した。腫瘍部分の短径(a
mm)と長径(bmm)とをノギスで測定し、1/2a2b
(mm3)を腫瘍容積とした。結果を第5図に示
す。さらに、移植後28日目に腫瘍部を切りとりそ
の重量を測定した。無処置マウス腫瘍部7.39gに
対して処置マウス腫瘍部は0.25g(T/C=5.2
%)であつた。またマウス5匹中3匹の腫瘍が消
失した。
第5図のグラフおよび上記の結果から、本発明
のセンダン樹皮熱水抽出物が定着固形ガンに対し
て顕著な効果を有することが明らかである。[Table] Test Example 4 Effect on established solid cancers 1 x 10 7 Sarcoma 180 cells were injected into ICR mice (5
The animals were transplanted subcutaneously to the back and reared as they were for 2 weeks. Sarcoma 180 implanted subcutaneously is 1000-1500
After confirming that the plant has grown to a size of 3 mm (approximately 12 x 15 mm), from the 14th day after transplantation, the purified meli bark hot water extract obtained in Example 8 was intraperitoneally administered once a day.
150mg/Kg was administered for 5 days. Short axis of tumor part (a
mm) and major axis (bmm) with a caliper, 1/2a 2 b
(mm 3 ) was defined as the tumor volume. The results are shown in Figure 5. Furthermore, on the 28th day after transplantation, the tumor area was cut out and its weight was measured. The tumor area of untreated mice was 7.39 g, while the tumor area of treated mice was 0.25 g (T/C = 5.2
%). Furthermore, the tumors in 3 out of 5 mice disappeared. From the graph of FIG. 5 and the above results, it is clear that the hot water extract of melium bark of the present invention has a remarkable effect on colonized solid cancer.
第1図は実施例8で得られたセンダン樹皮抽出
精製物の紫外線吸収スペクトルを示し、第2図は
同物質の赤外線吸収スペクトルを示す。第3図は
センダン樹皮を直接熱水で抽出して得られる公知
抽出物の紫外線吸収スペクトルを示し、第4図は
同物質の赤外線吸収スペクトルを示す。第5図は
試験例4の結果を示すグラフである。
FIG. 1 shows the ultraviolet absorption spectrum of the purified meli bark extract obtained in Example 8, and FIG. 2 shows the infrared absorption spectrum of the same substance. Figure 3 shows the ultraviolet absorption spectrum of a known extract obtained by directly extracting the bark of melium with hot water, and Figure 4 shows the infrared absorption spectrum of the same substance. FIG. 5 is a graph showing the results of Test Example 4.
Claims (1)
で抽出前処理し、得られた抽出残渣を熱水で抽出
処理して得られるセンダン樹皮熱水抽出物。 2 極性有機溶媒がアルコールである特許請求の
範囲第1項記載のセンダン樹皮熱水抽出物。 3 アルコールがメタノールである特許請求の範
囲第2項記載のセンダン樹皮熱水抽出物。 4 センダン樹皮を室温の水または極性有機溶媒
で抽出前処理し、得られた抽出残渣を熱水で抽出
処理し、得られた抽出液をアルコール沈澱法また
は透析膜法により精製して得られるセンダン樹皮
熱水抽出精製物。 5 アルコール沈澱法がエタノールを使用する沈
澱法である特許請求の範囲第4項記載のセンダン
樹皮熱水抽出精製物。 6 エタノールが50〜95%の濃度となる量該抽出
液に添加される沈澱法である特許請求の範囲第5
項記載のセンダン樹皮熱水抽出精製物。 7 透析法が分画分子量6000〜10000の透析膜を
使用する方法である特許請求の範囲第4項記載の
センダン樹皮熱水抽出精製物。 8 透析膜がスペクトラポア6(Spectra
Por6)(スペクトラム・メデイカル・インダスト
リー社製品)である特許請求の範囲第7項記載の
センダン樹皮熱水抽出精製物。[Scope of Claims] 1. A hot water extract of chili bark obtained by pre-extracting chili bark with water or a polar organic solvent at room temperature and extracting the resulting extraction residue with hot water. 2. The melium bark hot water extract according to claim 1, wherein the polar organic solvent is alcohol. 3. The melium bark hot water extract according to claim 2, wherein the alcohol is methanol. 4. Neil obtained by pre-extracting melium bark with water or a polar organic solvent at room temperature, extracting the resulting extraction residue with hot water, and purifying the resulting extract by alcohol precipitation or dialysis membrane method. Purified hot water extract of bark. 5. The purified hot water extract of melium bark according to claim 4, wherein the alcohol precipitation method is a precipitation method using ethanol. 6. Claim 5, which is a precipitation method in which ethanol is added to the extract in an amount to give a concentration of 50 to 95%.
Purified hot water extract of melium bark as described in . 7. The purified melium bark hot water extract according to claim 4, wherein the dialysis method is a method using a dialysis membrane with a molecular weight cutoff of 6,000 to 10,000. 8 The dialysis membrane is Spectrapore 6 (Spectra
Por6) (a product of Spectrum Medical Industries).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56146339A JPS5849318A (en) | 1981-09-18 | 1981-09-18 | Hot-water extract of bark of japanese bead tree |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56146339A JPS5849318A (en) | 1981-09-18 | 1981-09-18 | Hot-water extract of bark of japanese bead tree |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5849318A JPS5849318A (en) | 1983-03-23 |
| JPS6153335B2 true JPS6153335B2 (en) | 1986-11-17 |
Family
ID=15405453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56146339A Granted JPS5849318A (en) | 1981-09-18 | 1981-09-18 | Hot-water extract of bark of japanese bead tree |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5849318A (en) |
-
1981
- 1981-09-18 JP JP56146339A patent/JPS5849318A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5849318A (en) | 1983-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3434766C2 (en) | Pharmaceutical preparation | |
| GB2082066A (en) | Neem bark extracts possessing antineoplastic activities | |
| GB2120265A (en) | Polysaccharides their preparation and therapeutic compositions containing them | |
| EP0030812A2 (en) | A process for preparing substances having interferon inducing activity and interferon inducers | |
| GB2082061A (en) | Hot-water extracts of neem bark possessing antineoplastic activities | |
| US4614733A (en) | Polysaccharides pharmaceutical compositions and the use thereof | |
| JPS6153334B2 (en) | ||
| JPS6153335B2 (en) | ||
| US4831020A (en) | Ingredient effective for activating immunity obtained from Chlorella minutissima | |
| JPH0643330B2 (en) | Barley green juice hypoglycemic agent | |
| US4501736A (en) | Extract from barrenwort | |
| JPS6152808B2 (en) | ||
| JP4480204B2 (en) | Anti-tumor fraction of Kawariharatake | |
| US4442087A (en) | Interferon inducer, a process for producing the same and pharmaceutical composition containing the same | |
| JPS6213931B2 (en) | ||
| JPS6152809B2 (en) | ||
| JPS6153332B2 (en) | ||
| CN101612180B (en) | Preparation method of oleander polysaccharide extract and medical application of polysaccharide extract | |
| JPS6153333B2 (en) | ||
| JPS59184129A (en) | Polysaccharide t25g i and its preparation | |
| JPH0120132B2 (en) | ||
| KR840001510B1 (en) | Process for preparing extract from plant of genus epimedium s.p. | |
| JPS6216428A (en) | Biologically active substance obtained from tritonia crocosmaeflora lemoine and production thereof | |
| JPS6025931A (en) | Carcinostatic agent | |
| JPS61254528A (en) | Production of antitumor active substance |